Johnson & Johnson (JNJ) Shares Sold by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 7.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 10,697 shares of the company’s stock after selling 800 shares during the period. Gilman Hill Asset Management LLC’s holdings in Johnson & Johnson were worth $1,380,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Horan Securities Inc. grew its position in Johnson & Johnson by 122.3% during the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after buying an additional 241 shares during the period. Stuart Chaussee & Associates Inc. lifted its holdings in Johnson & Johnson by 20.7% during the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 80 shares in the last quarter. FNY Investment Advisers LLC lifted its holdings in Johnson & Johnson by 594.4% during the fourth quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock valued at $64,000 after purchasing an additional 428 shares in the last quarter. CKW Financial Group lifted its holdings in Johnson & Johnson by 18.8% during the fourth quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after purchasing an additional 128 shares in the last quarter. Finally, Mackey Komara & Dankovich LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $148,000. Hedge funds and other institutional investors own 66.91% of the company’s stock.

JNJ stock opened at $138.21 on Friday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.99. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $367.32 billion, a PE ratio of 16.90, a P/E/G ratio of 2.37 and a beta of 0.67.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the consensus estimate of $2.03 by $0.07. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The firm had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter in the previous year, the firm earned $2.06 earnings per share. The company’s quarterly revenue was up .1% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 8.6 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 11th. Stockholders of record on Tuesday, May 28th will be issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.75%. The ex-dividend date is Friday, May 24th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s payout ratio is 44.01%.

Several equities analysts have weighed in on the stock. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $152.00 to $156.00 and gave the company an “outperform” rating in a report on Thursday. Wells Fargo & Co reaffirmed an “outperform” rating and set a $157.00 price target (up previously from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. BMO Capital Markets lifted their price target on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a report on Wednesday, April 17th. Finally, Raymond James lifted their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus price target of $147.30.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by Gilman Hill Asset Management LLC” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.thelincolnianonline.com/2019/05/17/johnson-johnson-jnj-shares-sold-by-gilman-hill-asset-management-llc.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: How do candlesticks reflect price movement?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.